US21217B1008 - Common Stock
CONTINEUM THERAPEUTICS INC-A
NASDAQ:CTNM (10/22/2024, 2:58:23 PM)
16.19
+0.12 (+0.75%)
Contineum Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2024-04-05. Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its pipeline includes PIPE-791, CTX-343, and PIPE-307. Its lead asset, PIPE-791, is novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The firm is developing CTX-343, a peripherally restricted LPA1R antagonist to further expand clinical indications involving LPA1R antagonism. Its second drug candidate, PIPE-307, is a novel, small molecule, selective inhibitor of M1R, which is in clinical development for the potential treatment of depression and relapse remitting MS (RRMS).
CONTINEUM THERAPEUTICS INC-A
10578 Science Center Drive, Suite 200
San Diego CALIFORNIA
P: 18583335280
Employees: 31
Website: https://www.contineum-tx.com/
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Contineum Therapeutics (NASDAQ:CTNM) just reported results for the second quart...
CTNM stock results show that Contineum Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Here you can normally see the latest stock twits on CTNM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: